TLL-018, the dual JAK1/Tyk2 inhibitor which caused all the chatter at #EULAR2023, now with more full data showing it absolutely smash tofacitinib in RA, with similar safety. “This is a spectacular compound - unbelievably spectacular” - Roy Fleischmann #ACR23 ABST0840 @RheumNow https://t.co/nIKQb4yYrJ